Free Trial
NASDAQ:CVKD

Cadrenal Therapeutics (CVKD) Stock Price, News & Analysis

Cadrenal Therapeutics logo
$10.33 -0.09 (-0.86%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$10.35 +0.02 (+0.19%)
As of 08/1/2025 07:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Cadrenal Therapeutics Stock (NASDAQ:CVKD)

Key Stats

Today's Range
$10.17
$10.36
50-Day Range
$10.28
$15.49
52-Week Range
$5.70
$22.90
Volume
5,251 shs
Average Volume
26,199 shs
Market Capitalization
$20.32 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$32.00
Consensus Rating
Buy

Company Overview

Cadrenal Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
43rd Percentile Overall Score

CVKD MarketRank™: 

Cadrenal Therapeutics scored higher than 43% of companies evaluated by MarketBeat, and ranked 623rd out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Cadrenal Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Cadrenal Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Cadrenal Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Cadrenal Therapeutics are expected to grow in the coming year, from ($7.59) to ($3.81) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cadrenal Therapeutics is -1.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cadrenal Therapeutics is -1.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Cadrenal Therapeutics has a P/B Ratio of 2.48. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Cadrenal Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    1.53% of the float of Cadrenal Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Cadrenal Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cadrenal Therapeutics has recently increased by 2.01%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Cadrenal Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Cadrenal Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.53% of the float of Cadrenal Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Cadrenal Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cadrenal Therapeutics has recently increased by 2.01%, indicating that investor sentiment is decreasing.
  • Search Interest

    Only 1 people have searched for CVKD on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Cadrenal Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Cadrenal Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    48.62% of the stock of Cadrenal Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 7.92% of the stock of Cadrenal Therapeutics is held by institutions.

  • Read more about Cadrenal Therapeutics' insider trading history.
Receive CVKD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cadrenal Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CVKD Stock News Headlines

Elon’s BIGGEST warning yet?
Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.
See More Headlines

CVKD Stock Analysis - Frequently Asked Questions

Cadrenal Therapeutics' stock was trading at $14.49 on January 1st, 2025. Since then, CVKD stock has decreased by 28.7% and is now trading at $10.33.

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) announced its quarterly earnings data on Thursday, May, 8th. The company reported ($2.09) earnings per share for the quarter, missing the consensus estimate of ($1.64) by $0.45.

Cadrenal Therapeutics (CVKD) raised $7 million in an initial public offering (IPO) on Friday, January 20th 2023. The company issued 1,400,000 shares at $5.00 per share.

Shares of CVKD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cadrenal Therapeutics investors own include Clean Energy Fuels (CLNE), Paycom Software (PAYC), uniQure (QURE), AbCellera Biologics (ABCL), Grayscale Ethereum Trust (ETH) (ETHE), Mitsubishi UFJ Financial Group (MUFG) and Oatly Group (OTLY).

Company Calendar

Last Earnings
5/08/2025
Today
8/02/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CVKD
CIK
1937993
Fax
N/A
Employees
4
Year Founded
N/A

Price Target and Rating

High Price Target
$32.00
Low Price Target
$32.00
Potential Upside/Downside
+209.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Trailing Twelve Months)
($9.26)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$10.65 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-244.94%
Return on Assets
-181.94%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.32
Quick Ratio
4.32

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.17 per share
Price / Book
2.48

Miscellaneous

Outstanding Shares
1,967,000
Free Float
1,011,000
Market Cap
$20.32 million
Optionable
Not Optionable
Beta
0.95

Social Links

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (NASDAQ:CVKD) was last updated on 8/2/2025 by MarketBeat.com Staff
From Our Partners